34th week of 2022 patent applcation highlights part 9 |
Patent application number | Title | Published |
20220265591 | USE OF AN OSMOLYTE IN MANUFACTURE OF A MEDICAMENT FOR TREATMENT OF OCULAR DISORDERS - The present disclosure provides a use of an osmolyte in the manufacture of a medicament treating protein aggregation related disorders, specifically provides a use of an osmolyte in the manufacture of a medicament treating TGFBI corneal dystrophies. The osmolyte is selected from a group consisting of betaine, raffmose, sarcosine, taurine and/or any pharmaceutically acceptable derivatives thereof. | 2022-08-25 |
20220265592 | USE OF BIPOLAR TRANS CAROTENOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR TREATMENT OF CANCER - The subject disclosure relates to compounds and compositions including chemotherapy agents and/or radiation therapy with bipolar trans carotenoids, and the use of such compounds for the treatment of various cancers including pancreatic and brain cancers. | 2022-08-25 |
20220265593 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING OR PREVENTING HEMATOLOGIC DISORDERS, AND/OR RELATED DISEASES - The present disclosure relates to methods of treating or preventing hematologic disorders by administration of 15-HEPE or compositions thereof. | 2022-08-25 |
20220265594 | [((1R,2S,5R)-2-ISOPROPYL-5-METHYL-CYCLOHEXANECARBONYL)-AMINO]-ACETIC ACID ISOPROPYL ESTER FOR TREATMENT OF CHRONIC COUGH - The present invention pertains generally to the field of therapy. More specifically the present invention pertains to a certain compound, [((1R,2S,5R)-2-isopropyl-5-methyl-cyclohexanecarbonyl)-amino]-acetic acid isopropyl ester (also referred to herein as “AX-8” or “Gly-O-iPr”), as described herein, for use in a method of treatment of the human or animal body by therapy, more specifically, for use in a method of treatment of chronic cough (CC), including, for example, refractory chronic cough (RCC) and idiopathic chronic cough (ICC), as described herein. | 2022-08-25 |
20220265595 | ITACONIC ACID DERIVATIVES AND USES THEREOF INTREATING AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE - The invention relates to compounds of formula (IW-1) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R | 2022-08-25 |
20220265596 | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations - The present invention is directed to pharmaceutical formulations of therapeutic proteins that comprise one or more polyethoxylated fatty alcohol (PFA) surfactants that are resistant to lipase mediated degradation. The present invention is also directed to methods of reducing aggregate and/or particulate formation in pharmaceutical formulations of therapeutic proteins and methods of maintaining a stable surfactant level in pharmaceutical formulations of therapeutic proteins. | 2022-08-25 |
20220265597 | ANTIVIRAL EFFECTS OF NARASIN IN SWINE FEED - The present invention relates to a composition for ameliorating viral infections in nursery pigs. The composition contains the polyether ionophore narasin, and is supplied to the nursery pigs in an orally-acceptable form. The composition is effective in reducing viral shedding and the severity of diarrhea after challenge of nursery pigs with Porcine Epidemic Diarrhea Virus (PEDV). | 2022-08-25 |
20220265598 | EXTREME LOW DOSE THC AS A THERAPEUTIC AND PROPHYLACTIC AGENT FOR ALZHEIMER'S DISEASE - Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce Aβ protein levels; (ii) reduce Aβ aggregation: (iii) maintain AβPP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3β protein; (vi) decrease GSK-3β protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC. | 2022-08-25 |
20220265599 | ULTRA-LOW DOSE THC AS A POTENTIAL THERAPEUTIC AND PROPHYLACTIC AGENT FOR ALZHEIMER'S DISEASE - Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i)reduce Aβ expression; (ii) reduce Aβ aggregation: (iii) maintain APP expression; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK3β protein; (vi) decrease the expression of GSK3β protein; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein expression, in said patient without severe psychological impairments and side effects associated with higher doses of THC. | 2022-08-25 |
20220265600 | FORMULATIONS OF DIHYDROMYRICETIN AND A PERMEABILIZER - Formulations including dihydromyricetin (DHM) and a fatty acid salt or a fatty acid. | 2022-08-25 |
20220265601 | Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses. - The invention involves the use of formulations of positive, negative, inverse agonist, or neutral allosteric modulators of receptors such as, but not limited to: 5ht1a/b/c/d, 5ht2a/b/c, 5ht3, 5ht4, 5ht5, 5ht6, 5ht7, dopamine receptors (D1, D2, D3, D4, D5), adrenergic receptors (α1A, α1B, α2A, α2B, α2C, β1, β2), serotonin transporter (SERT), DA transporter (DAT), norepinephrine transporter (NET), imidazoline1 receptor (I1), Sigma receptors (σ1, σ2), delta opioid receptor (DOR), kappa opioid receptor (KOR), mu opioid receptor (MOR), muscarinic receptors (M1, M2, M3, M4, M5), histamine receptors (H1, H2), calcium ion channel (Ca+) and N-methyl D-aspartate (NMDA) glutamate receptor; alone or in combination with items such as, but not limited to: cannabinoids, terpenes, flavonoids, minerals, psychedelic and psychoactive compounds such as, but not limited to 5ht2a receptor agonists or other compounds; for medical, recreational, religious, research and other uses. | 2022-08-25 |
20220265602 | COMBINATION OF A CHROMENE COMPOUND AND A SECOND ACTIVE AGENT - The present disclosure provide a combination of a chromene compound having the structure of Formula (I), or pharmaceutically acceptable salts, and a second compound that can be selected from a PD-1 inhibitor, PD-L1 inhibitor, CTLA-4 inhibitor, OX-40 agonist, CD137 agonist, LAG-3 inhibitor, IDO inhibitor, bi-specific protein, EGFR inhibitor, HER2 inhibitor, and immune stimulating therapy and a method of using the combination for treating or preventing cancer. | 2022-08-25 |
20220265603 | HEPATIC FIBROSIS-INHIBITING AGENT AND BROWN FAT CELL-ACTIVATING AGENT CONTAINING TAXIFOLIN - The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient. | 2022-08-25 |
20220265604 | Treatment of mitochondrial diseases - The current invention concerns an innovative treatment for mitochondrial disorders and diseases or conditions associated with mitochondrial dysfunction. In particular, effective and safe dosages of compounds suitable for the treatment of mitochondrial disorders have been established, providing for new treatment regimens and patient populations. | 2022-08-25 |
20220265605 | METHODS OF INDUCING AUTOPHAGY USING COUMARIN DERIVATIVES AND RELATED COMPOUNDS - In various embodiments compounds that induce and/or promote autophagy are provided as wells as methods of use thereof (e.g., in the prophylaxis or treatment of chronic pathologies associated with aging). In one illustrative, but non-limiting embodiments the compound(s) comprise, inter alia, coumarin 106. | 2022-08-25 |
20220265606 | ANTICANCER AGENTS - In an embodiment, the present disclosure pertains to a method of treating a disease by induction of activity in cells. Generally, the method includes administering a bis-indole-derived compound to a subject in need thereof. In some embodiments, the method further includes binding, by the bis-indole-derived compound, to at least one of nuclear receptor 4A1 (NR4A1) and nuclear receptor 4A2 (NR4A2). In another embodiment, the present disclosure pertains to a compound for treating a disease by induction of activity in cells. Generally, the compound includes a bis-indole-derived compound. In some embodiments, the bis-indole-derived compound binds to at least one of NR4A1 and NR4A2. | 2022-08-25 |
20220265607 | METHODS AND COMPOSITIONS FOR UNSILENCING IMPRINTED GENES - The present invention provides methods and compositions for inducing expression of Ube3a in a cell and treating Angelman syndrome in a subject. | 2022-08-25 |
20220265608 | AUTOTAXIN INHIBITOR COMPOUNDS - Described herein are compounds that are autotaxin inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with autotaxin activity. | 2022-08-25 |
20220265609 | TARGETED EPIGENETIC THERAPY FOR INHERITED AORTIC ANEURYSM CONDITION - Transforming growth factor β (TGFβ) transcriptional responses are involved in the pathogenesis of aortic aneurism syndromes. Compositions that inhibit histone acetyltransferase activity normalize gene expression in the aorta, preserved aortic wall architecture and abrogated aneurism progression. Methods include the use of these compositions to epigenetically regulate abnormal expression and/or activity of TGFβ genes. | 2022-08-25 |
20220265610 | FORMULATIONS AND METHODS FOR THE TREATMENT OF CANCERS - The present invention is directed to a formulation for treating cancer comprising an androgen receptor signaling inhibitor and a B-cell-lymphoma-2 inhibitor, which may further comprising a Bromodomain-and-Extra-Terminal protein inhibitor or a phosphoinositide 3-kinase inhibitor. | 2022-08-25 |
20220265611 | ERGOTHIONEINE, S-METHYL-ERGOTHIONEINE, AND USES THEREOF - The present invention provides S-methyl-L-ergothioneine for use in diagnosis and/or prognosis. The invention also provides a method for the diagnosis and/or prognosis of a renal disease comprising the step of determining the amount of S-methyl-L-ergothioneine in an isolated test sample of a subject, and methods for deciding or recommending whether to initiate a therapeutic intervention or for determining the efficacy of a therapeutic intervention. It is also herein provided ergothioneine for use in the treatment and/or prevention of a renal lithiasis or an aminoaciduria, and ergothioneine for use in combination therapy. | 2022-08-25 |
20220265612 | CARDIAC SARCOMERE INHIBITOR ORAL FORMULATIONS - Provided herein are formulations comprising cardiac sarcomere inhibitor (R)-N-(5-(5-ethyl-1,2,4-oxadia-zol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, processes for making such formulations, and methods of treating various cardiac diseases and conditions with such formulations. | 2022-08-25 |
20220265613 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION - The present invention provides an oxazole compound represented by Formula (1), or a salt thereof: | 2022-08-25 |
20220265614 | TREATMENT COMPRISING FXR AGONISTS - The invention provides methods of treating, preventing, or ameliorating conditions mediated by farnesoid X receptors (FXR), in particular liver diseases or intestinal diseases, e.g. NASH, comprising administering to a subject in need thereof a therapeutically effective amount of a FXR agonist. | 2022-08-25 |
20220265615 | Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson?s Disease, Parkinson?s Disease with Dementia, Dementia with Lewy Bodies, and Multiple System Atrophy - The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof. | 2022-08-25 |
20220265616 | REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS - Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists. | 2022-08-25 |
20220265617 | BET INHIBITORS AS A TREATMENT FOR MYELOFIBROSIS - The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a BET (bromodomain and extra-terminal protein) inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more JAK inhibitors. Also provided are medicaments for use in treating cancer. | 2022-08-25 |
20220265618 | METHODS OF TREATING PROSTATE CANCER - The present application relates generally to methods for treating prostate cancer with substituted heterocyclic derivative 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2- methylisoquinolin-1-one as a bromodomain inhibitor, or the pharmaceutically acceptable salt thereof. | 2022-08-25 |
20220265619 | COMBINATION TREATMENT OF LIVER DISEASES USING FXR AGONISTS - The present invention relates to combinations for treating, preventing, or ameliorating conditions mediated by farnesoid X receptors (FXRs), in particular liver diseases or intestinal disease, comprising administering to a subject in need thereof a therapeutically effective amount of an FXR agonist. | 2022-08-25 |
20220265620 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS - The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. | 2022-08-25 |
20220265621 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS - The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof. | 2022-08-25 |
20220265622 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF - Provided herein is an amorphous compound represented by Formula (I): | 2022-08-25 |
20220265623 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF - Provided herein is an amorphous compound represented by Formula (I): | 2022-08-25 |
20220265624 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 2022-08-25 |
20220265625 | COMPOSITIONS AND METHODS USING TRIGONELLINE AND MINERALS FOR PREVENTING OR TREATING CONDITIONS OR DISORDERS IN SKELETAL MUSCLE - The present invention relates to compositions and methods for preventing or treating skeletal muscle conditions or dis- eases. The present invention also relates to compositions and methods that help to increase NAD+levels in skeletal muscle. Preferably, the present invention relates to compositions and methods that use trigonelline and minerals selected from the group consisting of: calcium, magnesium, sodium and/or potassium for preventing or treating skeletal muscle conditions or diseases. The recipient of the compositions of the invention can be, for example, an elderly individual or an individual with sarcopenia or an individual in need of the compositions and methods of the invention for recovery of skeletal muscles, for example, after exercise, muscle injury or surgery. | 2022-08-25 |
20220265626 | THE SERPINB3 INHIBITOR PIPERIDINPROPIONIC ACID FOR TUMOR TREATMENT - The invention concerns the use of 1-Piperidinpropionic acid or salts thereof, for the treatment of tumors that express SerpinB3. | 2022-08-25 |
20220265627 | TREATMENT OF PAIN AND NEUROLOGICAL CONDITIONS - The present disclosure is directed toward uses of compound 1 (or its stereoisomers) and compositions and/or dosage forms containing compound 1: | 2022-08-25 |
20220265628 | TREATMENT OF UROTHELIAL AND KIDNEY CANCERS BY USE OF ENDOTHELIN B RECEPTOR ANTAGONISTS - Disclosed herein are deuterated compounds, pharmaceutical compositions thereof, and methods for treating ETBR-related cancers such as urothelial, bladder, and kidney cancers. Also disclosed herein is a delivery system for the controlled, systemic release of at least one deuterated ETBR antagonist, optionally in conjunction with an additional anti-oncologic agent. | 2022-08-25 |
20220265629 | TREATMENT OF SYSTOLIC DYSFUNCTION AND HEART FAILURE WITH REDUCED EJECTION FRACTION WITH THE COMPOUND (R)-4-(1-((3-(DIFLUOROMETHYL)-1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-1-FLUORO- ETHYL)-N-(ISOXAZOL-3-YL)PIPERIDINE-1-CARBOXAMIDE - Provided herein are methods, use, and compositions for treating systolic dysfunction such as heart failure with reduced ejection fraction. | 2022-08-25 |
20220265630 | NICORANDIL DERIVATIVES - Disclosed herein are pyridyl compounds. Also described are specific conjugated nicorandil compounds. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the pyridyl compounds are disclosed for the treatment of diseases or conditions related to kidney or kidney functions. | 2022-08-25 |
20220265631 | OPHTHALMIC COMPOSITION - Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. | 2022-08-25 |
20220265632 | OPHTHALMIC COMPOSITION - Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein. | 2022-08-25 |
20220265633 | PHARMACEUTICAL COMPOSITIONS OF CABOZANTINIB - Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib. | 2022-08-25 |
20220265634 | METHODS AND USES FOR TREATING ANHEDONIA - The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A. | 2022-08-25 |
20220265635 | TREATMENT OF NEUROLOGICAL DISEASE - The invention is directed to 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding, heat shock factor 1 pathways, or nuclear erythroid 2-related factor 2 pathways. | 2022-08-25 |
20220265636 | ANTIMICROBIAL COMPOSITIONS - The present invention relates to antimicrobial compositions and more specifically compositions of quinolone carboxylic acid derivatives. These compositions have improved solubility, stability, and tolerability. These compositions are useful for intravenous administration for treating, preventing, or reducing the risk of infection. | 2022-08-25 |
20220265637 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Chemical entities that modulate PI3 kinase activity, pharmaceutical compositions containing the chemical entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein. | 2022-08-25 |
20220265638 | TREATMENT FOR EPILEPSY - The present invention discloses isoquinolines and 1H-2-Benzopyranes and their use in the treatment and prevention in epilepsy and other seizures. The present invention further discloses methods to screen isoquinoline- and 111- 2-Benzopyran- like molecules as pharmaceutically active compounds. | 2022-08-25 |
20220265639 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY - Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan. | 2022-08-25 |
20220265640 | METHODS OF ADMINISTERING NALBUPHINE - Provided herein are methods of treating nalbuphine-treatable disorders in a hepatically impaired patient. | 2022-08-25 |
20220265641 | SEROTONERGIC AGENT AND 5-HT1A-RECEPTOR ANTAGONIST - The present disclosure relates to a 5-HT1A-receptor antagonist or a derivative, precursor or metabolite thereof, in combination with at least one serotonergic agent or a derivative, precursor or metabolite thereof for use in the prevention and/or treatment of premature ejaculation, wherein the 5-HT1A-receptor antagonist or a derivative, precursor or metabolite thereof is administered separately, sequentially or simultaneously to the at least one serotonergic agent or a derivative, precursor or metabolite thereof. | 2022-08-25 |
20220265642 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR - The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. | 2022-08-25 |
20220265643 | DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF - Disclosed herein are novel methods of treating pain in a patient in need thereof by providing to the patient a selective dopamine D3 receptor antagonist/partial agonist which when used with an opioid analgesic, can mitigate the development of opioid dependence, by preventing the need for dose escalation while either maintaining the opioid analgesic effect or providing analgesia with a lower dose of the opioid. In addition, the D3 antagonists/partial agonists described herein may be used to augment the effectiveness of current Medication Assisted Treatment regimens (e.g. methadone or buprenorphine) for the treatment of opioid use disorders. | 2022-08-25 |
20220265644 | FIXED DOSE COMBINATION DRUG FOR THE TREATMENT OF MALARIA - A composition for treating malaria comprising Arterolane and Piperaquine is disclosed. The Arterolane and Piperaquine are present in an effective amount according a body-weight dosing regimen of a patient. | 2022-08-25 |
20220265645 | PYRAZINE-CONTAINING COMPOUND - Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may he used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling. | 2022-08-25 |
20220265646 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION - The present invention relates to diagnosing, preventing, delaying or reverting the progression of pathologies associated with abnormal amyloid deposits, such as that exemplified by Alzheimer's disease (AD). More specifically, the method involves administration of specific molecules that function as Piezo agonists, such as Yoda1, Jedi1, 5 Jedi2, or functional analogs thereof, that are able to modulate microglial activation towards anti-inflammatory state and/or interfere with the formation of amyloidogenic peptides and/or increase their efflux from the central nervous system. These agonists are applicable in disease states associated with, or at risk of, cerebral amyloidosis, such as AD, Parkinson's disease, stroke, head trauma(s), cerebral amyloid angiopathies, spongiform 10 encephalopathies and scrapie all of which are evidenced with abnormal proinflammatory microglial activation | 2022-08-25 |
20220265647 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods Comprising Them - The present invention relates to pharmaceutical compositions for inhalation comprising a therapeutically effective dose of clofazimine wherein the clofazimine is provided in the form of a suspension, and processes for their preparation. Furthermore, the present invention provides pharmaceutical combinations comprising clofazimine in the form of an aerosol for pulmonary inhalation. The combinations and compositions provided by the present invention may be used in the treatment and/or prophylaxis of pulmonary infections caused by mycobacteria and other gram-positive bacteria, and of pulmonary fungal infections. | 2022-08-25 |
20220265648 | Bromocriptine Formulations - The present disclosure describes pharmaceutical formulations of bromocriptine and method of manufacturing and using such formulations. The formulations are useful for treating physiological disorders including improving glycemic control in the treatment of type 2 diabetes. Also disclosed is synthesis of bromocriptine citrate, and compositions and dosage forms containing bromocriptine citrate. | 2022-08-25 |
20220265649 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES - Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof. | 2022-08-25 |
20220265650 | METHOD OF TREATING FIBROSIS - The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment. | 2022-08-25 |
20220265651 | PHARMACEUTICAL DOSAGE FORMS - The present invention relates to solid pharmaceutical dosage forms comprising the drug substance 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]pyrimidin-4-yl}-1-methyl-urea or any pharmaceutically acceptable salt thereof. It further relates to processes of making said solid pharmaceutical dosage forms. | 2022-08-25 |
20220265652 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS - The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto. | 2022-08-25 |
20220265653 | PHARMACEUTICAL COMPOSITION OF IMATINIB - A pharmaceutical composition having imatinib or its pharmaceutically acceptable salt thereof and one or more pharmaceutical acceptable excipients in powder form, which can be reconstituted with a diluent just before administration. Also disclosed is a process for the preparation of the composition and its use in a method for the treatment of cancer in pediatric patients. | 2022-08-25 |
20220265654 | DOSAGE REGIMENS FOR PARP7 INHIBITORS - The present invention is directed to dosing, dosage regimens, formulations, unit dosage forms, and related, of a PARP7 inhibitor for the treatment of cancer. The present invention is also directed to methods of treating cancer by administering the PARP7 inhibitor in combination with an antibody that binds to PD-1. | 2022-08-25 |
20220265655 | METHODS OF TREATING INFLAMMATORY DISEASES - The present invention relates to use of quinazolinones and related compounds which are inhibitors of PARP14 for the treatment and prevention of an inflammatory disease. | 2022-08-25 |
20220265656 | COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS - Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers. | 2022-08-25 |
20220265657 | ADMINISTRATION METHOD AND DOSAGE REGIMEN FOR TREATMENT OF NEURODEGENERATIVE DISEASES USING TRAMETINIB AND MARKERS - The present invention relates to administration methods and dosage regimens for treatment of neurodegenerative diseases using trametinib and markers. The administration methods and dosage regimens induce neural regeneration and changes in gene expression. | 2022-08-25 |
20220265658 | PHARMACEUTICAL COMPOSITION COMPRISING A TETRAHYDROPYRAZOLOPYRIMIDINONE COMPOUND - The invention relates to pharmaceutical compositions, which are self-emulsifying, self-microemulsifying, or self-nanoemulsifying in aqueous medium, comprising the compound: 2-(2,2-Difluoro-propyl)-5-[1-(2-fluoro-6-methyl-phenyl)-piperidin-4-yl]-7-(2-trifluoromethyl-benzyl)-2,4,5,7-tetrahydro-pyrazolo[3,4-d]pyrimidin-6-one | 2022-08-25 |
20220265659 | METHODS AND COMPOSITIONS FOR TREATING PAX6-DEFICIENCY RELATED DISEASE - The present invention relates to an agent for increasing PAX6 gene and/or protein expression in a subject in need thereof. The insertion of a nonsense mutation found in patients allowed inventors to identify altered gene expression of PAX6 target genes, enhanced cell adhesion and reduced cell migration and proliferation. Remarkably, these parameters were rescued by recombinant PAX6 protein. Using this unique cellular model in which they inserted multiple copies of PAX6 responsive elements and tdTomato, they screened a FDA-approved library and identified in a first hit, 3 small compounds that enhance production of PAX6 protein while two of them did not modulate PAX6 gene expression. More particularly, they observed that the small compounds efficiently rescue in vitro migration of mutated limbal cells. Moreover, in the art, it is known that a decrease of PAX6 leads to an induction of diabetes. Small compounds identified by the inventors are suitable to treat PAX6-related deficiencies diseases such as aniridia and diabetes. | 2022-08-25 |
20220265660 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS - Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described. | 2022-08-25 |
20220265661 | USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELL - Problem: to provide an activator for activating intracellular ATP production. Solution: use of a pyridodipyrimidine compound represented by the following formula (II): | 2022-08-25 |
20220265662 | USE OF COENZYME FACTOR FOR ACTIVATION OF ATP PRODUCTION IN CELL - Problem: to provide an activator for activating intracellular ATP production. Solution: use of deazaflavino-testosterone compound represented by the following formula (III): | 2022-08-25 |
20220265663 | Composition for Treatment of Muscular Disorders - The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia. | 2022-08-25 |
20220265665 | TRIAZINE FORMULATIONS WITH A SECOND ACTIVE INGREDIENT AND SURFACTANT(S) - The present invention is related to novel compositions comprising at least one active ingredient of the family of the triazines combined with another active ingredient and specific compounds that allow the reduction of foam formation. More particularly, the invention relates to compositions in the form of aqueous suspensions comprising a triazine, an iron complex, and one or more surfactant(s) having a particular HLB. | 2022-08-25 |
20220265666 | METHODS OF TREATING SUBSTANCE ABUSE DISORDER, DYSPNEA, TINNITUS, AND CHILD AND ADOLESCENT DEPRESSION - The present invention relates to methods for the treatment of substance abuse disorder, dyspnea, tinnitus, child and adolescent depression, child and adolescent suicidal ideation and behavior, and child and adolescent anxiety using etifoxine or a pharmaceutically acceptable salt thereof. | 2022-08-25 |
20220265667 | ETIFOXINE FOR USE IN THE TREATMENT OF DISEASES RELATED TO ACTIVATED MAST CELLS - Etifoxine, or a pharmaceutically acceptable derivative thereof, can be used for the treatment of a disease related to activated mast cells in a subject, preferably a human. Furthermore, a pharmaceutical composition containing Etifoxine, or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable excipient can be used for the treatment of a disease related to activated mast cells. An in vitro or ex-vivo method of inhibiting mast cell activation, involves contacting a cell with Etifoxine, or a pharmaceutically acceptable derivative thereof. | 2022-08-25 |
20220265668 | TREATMENT AND/OR PREVENTION OF LESIONS IN THE CENTRAL AUDITORY NERVOUS SYSTEM - The therapeutic use of azasetron or an analogue thereof for treating and/or preventing a lesion in the central auditory nervous system (CANS) in an individual. The treatment of lesions in the CANS with azasetron also prevents, inhibits, and/or reduces the loss of the central auditory neuron cells in the brainstem. | 2022-08-25 |
20220265669 | COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS - The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables R | 2022-08-25 |
20220265670 | COMPOSITION AND USE THEREOF FOR THE TREATMENT OF CUTANEOUS MASTOCYTOSIS - The invention provides topical pharmaceutical compositions and use thereof for treating or lessening the symptoms of, or preventing the symptoms of cutaneous mastocytosis. | 2022-08-25 |
20220265671 | METHOD FOR TREATING STROKE BY USING TRICYCLIC DERIVATIVE - A method for treating stroke by using a tricyclic derivative is described. More specifically, a dose and a regimen of administrating a tricyclic derivative that can exhibit optimal efficacy and effect as a therapeutic agent for use in treating a stroke patient are provided. The treatment method has the advantage of exhibiting optimal efficacy and effects while safely administering a novel tricyclic derivative. | 2022-08-25 |
20220265672 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE - Disclosed herein include methods, compositions, and kits suitable for use in preventing and treating Alzheimer's disease. In some embodiments, methods of delaying or reducing the likelihood of onset of Alzheimer's disease are provided. The method can comprise administering to a subject in need thereof a composition comprising a neurokinin 1 receptor (NK1R) antagonist (e.g., aprepitant). | 2022-08-25 |
20220265673 | COMBINATION THERAPY - Provided herein are methods of treating diseases, such as cancer, using a combination therapy. In certain embodiments, the methods comprise administering an effective amount of a phosphoinositide-3-kinase (PI3K) inhibitor and an effective amount of a CD20 inhibitor to a patient. | 2022-08-25 |
20220265674 | PARENTERAL COMPOSITIONS COMPRISING METHYLENE BLUE - The present invention relates to parenteral compositions comprising methylene blue, water and one or more pH regulating agents. The present invention also relates to processes for preparing such compositions. | 2022-08-25 |
20220265676 | TRICYCLIC DIBENZOTHIAZEPINE TYPE COMPOUNDS FOR USE IN THE THERAPY OF CDKL5 DISORDER - Tricyclic dibenzothiazepine compounds for use in the treatment of CDKL5 disorder. Specifically, a compound of Formula I, or a pharmaceutically or veterinarily acceptable salt thereof, or a pharmaceutically or veterinarily acceptable solvate of either entity for use in the treatment of CDKL5 disorder in a mammal, wherein a compound of Formula I comprises: | 2022-08-25 |
20220265677 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MUSCLE CONDITIONS - Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein. | 2022-08-25 |
20220265678 | PREFERRED ORAL TESTOSTERONE UNDECANOATE THERAPY TO ACHIEVE TESTOSTERONE REPLACEMENT TREATMENT - The present invention features new testosterone undecanoate (TU) dosing regimens, e.g., for testosterone replacement therapy. The TU may be formulated with phytosterols or phytosterol esters. | 2022-08-25 |
20220265679 | PROLIPOSOMAL TESTOSTERONE UNDECANOATE FORMULATIONS - This invention relates to proliposomal powder dispersions of testosterone undecanoate (TU) and phospholipids, including dispersions of TU and palmitoylphosphatidylcholine (DPPC), wherein the weight/weight (w/w) ratio of TU:DPPC in the proliposomal powder dispersion is about 1:2; or TU and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), wherein the weight/weight (w/w) ratio of TU:DMPC in the proliposomal powder dispersion is about 1:3; or TU and a 1-myristoyl-2-palmitoyl-sn-glycero 3-phosphocholine (MPPC), wherein the weight/weight (w/w) ratio of TU:MPPC in the proliposomal powder dispersion is about 1:3. | 2022-08-25 |
20220265680 | GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS - This invention relates to methods for treating status epilepticus by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides SE suppression and continued suppression of SE. | 2022-08-25 |
20220265681 | ABIRATERONE PRODRUGS - Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, an androgen receptor driven cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia. | 2022-08-25 |
20220265682 | DRUG COMPOSITION CONTAINING ABIRATERONE ACETATE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - A drug composition containing abiraterone acetate, and a preparation method therefor and an application thereof. Excipients thereof comprise at least one oil phase, at least one emulsifier, and at least one co-emulsifier. The dug composition can obviously improve the bioavailability and the stability of a preparation. The drug composition can be further prepared as capsules. ( | 2022-08-25 |
20220265683 | HALOGENATED SALICYLANILIDES FOR THE TREATMENT OF DERMATITIS - The present invention relates to halogenated salicylanilides for use in the treatment of dermatitis in a human subject, for example atopic dermatitis in a human subject. | 2022-08-25 |
20220265684 | COMPOSITIONS AND METHODS FOR TREATING ULCERATIVE COLITIS - The invention, in various aspects and embodiments, provides compositions and methods for treating or managing ulcerative colitis (UC) (including mild or moderate UC), including intestinal and extraintestinal symptoms, including but not limited to arthritis. The compositions and methods in various embodiments relate to oral administration of pharmaceutical compositions that comprise an effective amount of one or more agents that forms at least one 4-APAA compound by azo reduction in the colon. In various embodiments, active agent is available for local action in the lumen of the large intestine. Further, as described herein, a significant portion of the 4-APAA formed by azo reduction in the large intestine is systemically available to ameliorate extraintestinal symptoms. | 2022-08-25 |
20220265685 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - The invention relates to methods and compositions for improving cognitive function by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an acetylcholinesterase inhibitor (AChEI) or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In particular, it relates to the use of a combination of an SV2A inhibitor and an AChEI in treating a central nervous system disorder with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis (ALS), and cancer-therapy-related cognitive impairment. | 2022-08-25 |
20220265686 | FOSPROPOFOL METHODS AND COMPOSITIONS - The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed. | 2022-08-25 |
20220265687 | Di-Isopropyl-Phosphinoyl -Alkanes as topical agents for the treatment of sensory discomfort - The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders. | 2022-08-25 |
20220265688 | STABLE ORAL COMPOSITION OF CYCLOPHOSPHAMIDE - A stable oral composition for cyclophosphamide or its pharmaceutically acceptable salt. The composition for cyclophosphamide can be in the form of powder for oral solution, which can provide an improved stability, ease for reconstitution, and better palatability suitable for pediatric patients. Also disclosed is a process for preparation of the powder for oral solution of cyclophosphamide. | 2022-08-25 |
20220265689 | HIV PRE-EXPOSURE PROPHYLAXIS - Disclosed is the use of a nucleoside reverse transcriptase inhibitor, a nucleotide reverse transcriptase inhibitor, and an integrase inhibitor prior to an exposure to a potential human immunodeficiency virus (HIV) infection, to protect the subject from the HIV infection. In some embodiments, a prophylactically effective amount of emtricitabine (FTC), a prophylactically effective amount of tenofovir or a tenofovir prodrug, such as tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF), a prophylactically effective amount of the integrase inhibitor elvitegravir (EVG), and optionally cobicistat (COBI) are used to inhibit or prevent an HIV infection, wherein these agents are administered only prior to the exposure. In specific non-limiting examples, only one dose of the anti-retroviral viral agents is administered to a subject prior to the exposure. | 2022-08-25 |
20220265690 | USE OF SOTAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AND MODERATE RENAL IMPAIRMENT - The invention relates to the use of sotagliflozin inpatients with type 2 diabetes mellitus and moderate renal impairment. | 2022-08-25 |
20220265691 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES - Cancer patients that express high levels of the E-selectin ligand (sialyl Le | 2022-08-25 |
20220265692 | ORALLY-ADMINISTERED PHARMACEUTICAL COMPOSITION FOR ERADICATING ANTIBIOTIC-RESISTANT HELICOBACTER PYLORI, COMPRISING COMPLEX OF NON-ABSORBABLE ANTIBIOTIC AND CLAY MINERAL - Disclosed is an orally-administered pharmaceutical composition or kit for eradicating | 2022-08-25 |